Skip to content

Advertisement

  • Research
  • Open Access

Arginine does not rescue p.Q188R mutation deleterious effect in classic galactosemia

  • 1, 2, 3,
  • 1, 2, 3,
  • 4,
  • 5,
  • 5,
  • 5,
  • 6,
  • 6,
  • 7,
  • 7,
  • 8,
  • 8,
  • 8,
  • 8,
  • 1,
  • 1,
  • 1, 2, 3Email author and
  • 1, 2, 3
Contributed equally
Orphanet Journal of Rare Diseases201813:212

https://doi.org/10.1186/s13023-018-0954-8

  • Received: 16 August 2018
  • Accepted: 14 November 2018
  • Published:

Abstract

Background

Classic galactosemia is a rare genetic metabolic disease with an unmet treatment need. Current standard of care fails to prevent chronically-debilitating brain and gonadal complications.

Many mutations in the GALT gene responsible for classic galactosemia have been described to give rise to variants with conformational abnormalities. This pathogenic mechanism is highly amenable to a therapeutic strategy based on chemical/pharmacological chaperones. Arginine, a chemical chaperone, has shown beneficial effect in other inherited metabolic disorders, as well as in a prokaryotic model of classic galactosemia.

The p.Q188R mutation presents a high prevalence in the Caucasian population, making it a very clinically relevant mutation. This mutation gives rise to a protein with lower conformational stability and lower catalytic activity. The aim of this study is to assess the potential therapeutic role of arginine for this mutation.

Methods

Arginine aspartate administration to four patients with the p.Q188R/p.Q188R mutation, in vitro studies with three fibroblast cell lines derived from classic galactosemia patients as well as recombinant protein experiments were used to evaluate the effect of arginine in galactose metabolism. This study has been registered at https://clinicaltrials.gov (NCT03580122) on 09 July 2018. Retrospectively registered.

Results

Following a month of arginine administration, patients did not show a significant improvement of whole-body galactose oxidative capacity (p = 0.22), erythrocyte GALT activity (p = 0.87), urinary galactose (p = 0.52) and urinary galactitol levels (p = 0.41). Patients’ fibroblasts exposed to arginine did not show changes in GALT activity. Thermal shift analysis of recombinant p.Q188R GALT protein in the presence of arginine did not exhibit a positive effect.

Conclusions

This short pilot study in four patients homozygous for the p.Q188R/p.Q188R mutation reveals that arginine has no potential therapeutic role for galactosemia patients homozygous for the p.Q188R mutation.

Keywords

  • Classic galactosemia
  • Inherited metabolic disorder
  • Galactose metabolism
  • Arginine
  • Amino acid supplementation
  • Chemical chaperones

Background

Classic galactosemia (CG) (OMIM #230400) is a rare metabolic disease caused by a severe deficiency of galactose-1-phosphate uridylyltransferase (GALT), the second enzyme of the main pathway for galactose metabolism. It is an autosomal recessive disorder with a prevalence of 1:16,000 to 1:50,000 live births in Western countries.

Classic galactosemia represents a high burden in the lives of patients and families [1]. Its current standard of care, a galactose-restricted diet, even though life-saving in the neonatal period, fails to prevent chronically-debilitating complications, such as brain, gonadal and social impairments. Brain complications result in cognitive, behavioral and neurological complications. Patients often achieve a lower grade of education and occupation, they are often shy and less often succeed in building a relationship outside the family. More than 80% of female patients suffer from primary ovarian insufficiency (POI) with subsequently subfertility [2, 3]. Therefore, new therapeutic strategies are needed.

Several mutations in the GALT gene have been described to give rise to variants with a severely impaired catalytic activity due to GALT misfolding and/or aggregation in yeast and bacterial (E. coli) models [4, 5]. Notably, variant p.Q188R presented a strikingly high aggregation propensity [5]. Recently, the crystal structure of human GALT was determined by McCorvie et al. [6], providing a molecular framework to understand disease-causing mutations at the protein level. The c.563A > G (p.Q188R) mutation, the most frequent GALT mutation in the Caucasian population (> 60 to > 90% prevalence) [7] was described to give raise to a protein with reduced conformational stability and catalytic activity [6].

A promising therapeutic approach for conformational disorders focuses on the use of chemical/pharmacological chaperones [810]. Arginine is a chemical chaperone described to act as a selective inhibitor of undesirable protein aggregation [11, 12].

In vitro studies using a prokaryotic model of classic galactosemia revealed that arginine might be of potential value for a number of clinically-relevant mutations, including p.Q188R [13].

Studies in fibroblasts from patients with a mild peroxisomal biogenesis disorder revealed that arginine exerted a positive effect on the peroxisome function [14]. More recently, Sorlin et al. described the case of a patient with PEX12 deficiency that showed a positive effect at the biochemical and neurophysiological levels following 12 months of treatment with arginine [15]. Additionally, administration of arginine aspartate (in the commercially available form of Asparten®) was reported to have positive clinical and biochemical effects in a patient with pyruvate dehydrogenase deficiency (PDHc) [16].

The aims of this study were to evaluate the potential therapeutic role of arginine in classic galactosemia caused by the p.Q188R mutation.

Results

Arginine aspartate supplementation in patients

Four classic galactosemia patients homozygous for the c.563A > G (p.Q188R) mutation were enrolled in the clinical study. Patients’ characteristics are presented in Table 1.
Table 1

Patients’ characteristics

 

Patient 1

Patient 2

Patient 3

Patient 4

Age (years)

29

21

19

24

Gender

Male

Female

Male

Female

Ethnicity

Caucasian

Caucasian

Caucasian

Caucasian

Genotype

p.Q188R/p.Q188R

p.Q188R/p.Q188R

p.Q188R/p.Q188R

p.Q188R/p.Q188R

Patients’ characteristics of the four classic galactosemia patients enrolled in the clinical study

Assessments of the effect of arginine aspartate supplementation (Asparten®) included whole body galactose oxidative capacity (primary outcome), erythrocyte GALT activity, as well as urinary galactose and galactitol levels (secondary outcomes). Baseline results were obtained immediately before Asparten® supplementation. Post treatment results were obtained after 30 ± 5 days of Asparten® intervention, immediately after suspension of treatment.

No significant difference in the profile of mean galactose oxidative capacity was observed (Fig. 1 and Additional file 1: Figure S1). The CUMPCD (cumulative percent of the dose) for the total time of the study (360 min) per patient is shown in Table 2. At baseline, the mean 13CO2 released by the four patients was 2.8 ± 1.3%, whereas after intervention it was 2.7 ± 1.2% (p = 0.22).
Fig. 1
Fig. 1

Mean galactose oxidative capacity before and after arginine aspartate supplementation. Mean galactose oxidative capacity of the four patients, expressed as CUMPCD (cumulative percent of the dose) 13CO2 eliminated in air. Baseline: CUMPCD (120 min) = 0.7 ± 0.06%; CUMPCD (360 min) = 2.8 ± 1.3%. After intervention: CUMPCD (120 min) = 0.7 ± 0.02%; CUMPCD (360 min) = 2.7 ± 1.2%

Table 2

Primary and secondary outcomes of the clinical study

 

Patient 1

Patient 2

Patient 3

Patient 4

Baseline

After treatment

Baseline

After treatment

Baseline

After treatment

Baseline

After treatment

CUMPCD 13CO2 at 360 min (%)a

2.5

2.6

2.8

2.8

2.9

2.6

3.0

2.7

GALT activity (μmol/h/mmol Hb)

6.7 (1.2%)

6.1 (1.1%)

11.3 (2.0%)

16.0 (2.8%)

8.8 (1.5%)

5.7 (1.0%)

6.9 (1.2%)

6.9 (1.2%)

Galactitol in urine (μmol/mmol creatinine)

115

123

132

123

114

106

93

87

Galactose in urine (μmol/mmol creatinine)

6

11

5

6

8

5

24

7

Dietary arginine intake (g/day)

6

6

4

3

4

4

3

4

Compliance to Asparten ® (%)

100

93

92

98

Days of treatment

28

28

35

35

Supplementation of arginine aspartate (Asparten®) was evaluated by whole body galactose oxidative capacity (primary outcome), erythrocyte GALT activity, as well as urinary galactose and galactitol levels (secondary outcomes). Baseline evaluation was done immediately before the initiation of Asparten® supplementation, after treatment evaluation was done immediately after suspension of Asparten® supplementation

a CUMPCD (cumulative percent of the dose) 13CO2 eliminated in air at 360 min

GALT activity before and after intervention is represented in Fig. 2. There was no statistically significant (p = 0.87) increase in GALT activity following arginine aspartate supplementation (baseline: 8.4 ± 2.2 μmol/h/mmol Hb, corresponding to 1.5%; after treatment: 8.7 ± 4.9 μmol/h/mmol Hb, corresponding to 1.5%) (Table 2).
Fig. 2
Fig. 2

Mean GALT activity before and after arginine aspartate supplementation. GALT activity is expressed as μmol of UDP-Gal formed per hour per mmol hemoglobin

Mean urinary galactitol and galactose levels are shown in Fig. 3. Both metabolites did not show a statistically significant decrease after arginine aspartate supplementation. Galactitol decreased from 114 ± 16 to 110 ± 17 μmol/mmol creatinine (p = 0.41) (reference 0–125 μmol/mmol creatinine) and galactose decreased from 11 ± 9 to 7 ± 3 μmol/mmol creatinine (p = 0.52) (Table 2).
Fig. 3
Fig. 3

Mean urinary galactitol and galactose levels before and after arginine aspartate supplementation

Amino acid profile analysis revealed that plasma arginine decreased from 67 ± 17 μmol/L at baseline to 53 ± 21 μmol/L following intervention (p = 0.05) (reference 16–124.9 μmol/L). Additionally, patients exhibited on average an increase in plasma ornithine levels from 66 ± 25 μmol/mmol at baseline to 142 ± 73 μmol/L following intervention (p = 0.07) (reference 24.0–167.9 μmol/L). Other amino acids did not show any significant difference between baseline and after intervention.

The mean dietary arginine intake did not increase during study (4 ± 1 g/day at baseline and after treatment) (p = 0.87). Mean daily galactose intake did not change during study period. All patients showed a high compliance to Asparten® intake, ranging from 92 to 100% (Table 2).

Patient 1 reported headache in the first two days of Asparten® supplementation.

Arginine exposure of patients’ fibroblasts

In parallel with the clinical analysis, fibroblasts derived from two p.Q188R/p.Q188R patients and one p.Q188R/p.Q188P patient were cultured in the presence and absence of arginine. GALT activity of exposed and unexposed fibroblasts is presented in Table 3. Patients’ fibroblasts displayed no detectable activity even in the presence of a high concentration of arginine (1 mM). In order to discard possible arginase activity, arginine in the cell culture medium was measured. Results are presented in Additional file 2: Table S1.
Table 3

GALT enzymatic activity in fibroblasts exposed to arginine

GALT activity (μmol/h/g protein)

Cell line

No arginine

0.1 mM arginine

1 mM arginine

Control 1 (n = 3)

31.6 ± 12.9

45.6 ± 25.1

35.3 ± 21.3

Control 2 (n = 2)

52.9

46.1

42.9

CG 1 (n = 2)

n.d.

n.d.

n.d.

CG 2 (n = 2)

n.d.

n.d.

n.d.

CG 3 (n = 2)

n.d.

n.d.

n.d.

Two wildtype (controls 1 and 2) and three classic galactosemic fibroblasts derived from two p.Q188R/p.Q188R patients (cell lines CG1 and CG2) and a p.Q188R/p.Q188P patient (cell line CG3) were cultured in the absence and in the presence of supplemental arginine (0.1 mM and 1 mM arginine). Results are expressed as μmol per hour per gram protein and presented as mean ± SD or average for n = 2. Number of replicates is presented in brackets

n.d.: non-detectable

Thermal shift assay of recombinant human GALT in the presence of arginine

The therapeutic benefit of arginine was previously attributed to a possible role as chemical chaperone, stabilizing disease-associated proteins. To investigate this possibility, the in vitro thermal shift assay (differential scanning fluorimetry, DSF) was performed to evaluate whether arginine could thermally stabilize recombinant GALT (Table 4 and Fig. 4). Neither the p.Q188R or the wildtype GALT protein showed a thermal shift in the presence of arginine at any of the concentrations studied. In contrast, galactose (10 mM), a moiety of the substrate galactose-1-phosphate, caused a small shift in the melting temperature of the wildtype protein (ΔTm = 2.3 °C) but not of the p.Q188R variant (ΔTm = 1.4 °C).
Table 4

Thermal shift assay of wildtype and p.Q188R GALT

Melting temperature (Tm, °C)

 

Wildtype GALT

p.Q188R GALT

None

55.8 ± 0.2

54.6 ± 0.2

Arginine

54.8 ± 0.1

54.7 ± 0.4

Galactose

58.1 ± 0.4

56.0 ± 0.3

Comparison of temperature at which half the protein was unfolded (melting temperature, Tm) with no added ligand, arginine (10 mM) or galactose (10 mM). Values presented are the mean values of three replicates

Fig. 4
Fig. 4

Representative thermal shift assay curves with no added ligand, arginine (10 mM) or galactose (10 mM) for A. wildtype GALT and B. p.Q188R GALT. Fluorescence values were normalized to allow comparison of Tm values. Curves for single replicate per ligand state plotted, with no added ligand, arginine (10 mM) or galactose (10 mM). Values stated are the mean values of three replicates

Discussion

In this study we evaluated the potential therapeutic role of arginine in classic galactosemia caused by c.563A > G (p.Q188R) mutation at three different levels: patients, fibroblast galactosemic cell lines and recombinant protein studies.

Patients were treated with arginine aspartate (in the commercially available form of Asparten®) in a dose of 15 g/day for one month. Arginine aspartate supplementation (Asparten®) did not enhance galactose oxidation rates or improve the biochemical profile in CG patients.

Whole body galactose oxidative capacity was evaluated for 6 h (360 min) after administrating a bolus injection of [1-13C]-galactose. The overall profile of galactose oxidative capacity did not show an increase following intervention (p = 0.22) (Fig. 1 and Additional file 1: Figure S1). All patients exhibited a CUMPCD less than 2% at 120, before and after treatment, consistent with a severe GALT deficiency, as described by Berry et al. [17].

GALT activity analysis in red blood cells (RBC) revealed no statistically significant difference after treatment compared to baseline. Galactose metabolite concentrations did not significantly change.

All patients continued with their galactose-restricted diet, the lifelong mainstay of treatment in classic galactosemia nowadays.

Amino acid profile analysis revealed that plasma arginine decreased whereas ornithine levels increased. It is known that arginase, the enzyme responsible for the conversion of arginine into ornithine, exhibits an increased transcription and activity upon exposure to exogenous arginine [18], which very likely accounted for the observed inverse plasmatic concentrations of these amino acids.

No adverse events have ever been reported since Asparten® entered in the market in 1974. In this study, arginine was well tolerated, but patient 1 reported headache in the first two days of Asparten® supplementation. This could possibly be due to vasodilation caused by nitric oxide production (NO) [19].

All patients showed a high compliance to Asparten® (93 to 100%) which suggests that the observed lack of efficacy was not due to low adherence to intervention. Dietary arginine intake was also evaluated due to its potential to influence results. At baseline, the arginine intake of patient 1 was nearly the double of that of the other patients (92% higher) and after treatment it was 123% of that of the other patients, which might suggest that increasing Asparten® administration would not improve the biochemical phenotype. It is important to keep in mind, however, that the metabolism of dietary arginine and Asparten® supplementation might differ, e.g. at the bioavailability level.

This is the first study to investigate the effect of arginine aspartate (Asparten®) supplementation in classic galactosemia. Asparten® has shown a positive effect in a PDHc deficient patient [16]. After 1 month of Asparten® administration, the 6-year-old patient showed a striking improvement on both biochemical and clinical outcomes. The patient was on a daily dose of 5 g arginine aspartate (Asparten®). In the present study, the adult patients were on a daily dose of 15 g arginine aspartate (Asparten®). However, Asparten® did not ameliorate the biochemical phenotype of the studied patients.

These findings contradict the previous study on the prokaryotic model of galactosemia, in which arginine supplementation to the medium in a concentration of 25 mM partially rescued the bacterial culture expressing human GALT p.Q188R [13]. These discrepancies might stem from the high arginine concentration used in the prokaryotic model.

Limitations of this study are the small number of subjects and relatively short duration of Asparten® supplementation. With respect to the RBC GALT activity, the lifespan of erythrocytes is about 120 days, both in galactosemic and in non-galactosemic patients. Since the study was conducted for 1 month, the effect of Asparten® on the GALT activity could be underestimated [20, 21]. The short duration of the study was also insufficient to evaluate Asparten® effects on long-term clinical outcomes. Furthermore, younger patients could have responded differently to Asparten®‘s treatment. However, neither fibroblast assays nor in vitro studies using recombinant human p.Q188R GALT showed a positive effect, which suggests that arginine’s mechanism of action as a chemical chaperone is not effective for this GALT variant.

These findings do not preclude that arginine could be successfully used in patients carrying other GALT mutations that lead to a conformational change without irreversibly affecting the catalytic activity. Further studies are warranted to gain more insight in arginine’s potential effect on other less frequent GALT mutations.

Recently, the crystallographic structure of human GALT has been reported [6], and will contribute for the development of GALT-based therapeutic approaches, namely pharmacological chaperones (PCs). PCs are a promising therapeutic approach in protein misfolding diseases. PCs bind specifically to the target protein and shift the equilibrium towards the correctly folded state of the protein. A number of pharmacological chaperones has been successfully developed in the field of inherited metabolic disorders (reviewed in ref. [10, 22]). Arginine is a chemical chaperone described to act as a selective inhibitor of undesirable protein aggregation [11, 12].

The new knowledge and understanding gained with the human GALT crystal structure holds great promise for the development of a PC-based therapeutic approach for CG. Furthermore, the crystal structure will also guide other developments of therapies for this disease, besides the PC-based approach. Other therapeutic approaches include substrate reduction therapies by GALK1-inhibitors, superoxide dismutase and enzyme replacement therapy to increase the activity of human GALT.

Conclusion

In conclusion, the results of this pilot study suggest that neither arginine nor arginine aspartate (Asparten®) would be therapeutically effective in galactosemia patients homozygous for the c.563A > G (p.Q188R) mutation under the presented conditions. Nevertheless, these findings do not preclude that arginine could be successfully used in patients carrying other GALT mutations. Further studies are warranted to gain more insight in arginine’s effect on other GALT mutations.

Patients and methods

Patients

Four adult classic galactosemia patients being followed up in our expertise centrum for classic galactosemia carrying the p.Q188R mutation in homozygosity were included in the study (Table 1). Written informed consent was obtained from all patients participating in the study. The study was approved by the Medical Ethical Committee of the Maastricht University Medical Center + (METC). This study has been registered at https://clinicaltrials.gov (NCT03580122).

Study design and intervention

This is a study with a pre-post single arm design. All patients received arginine in the commercially available form of arginine aspartate (Asparten®). This formula was chosen based on the fact that it is administered by oral route and it displays well-known pharmacokinetic and toxicological characteristics. It is commercialized since 1974 and no side effects have ever been described. Each ampoule of Asparten® contains 5 g of arginine aspartate. Following the screening and baseline assessments, patients received 5 g of arginine aspartate, 3 times a day (as recommended in Asparten®‘s Summary of Product Characteristics), corresponding to a daily dose of 15 g arginine aspartate. Duration of the intervention was 1 month (30 ± 5 days). Patients were asked to keep the empty ampoules in order to ascertain compliance to intervention.

Diet

All patients remained on a galactose-restricted diet, which consists of eliminating all galactose- and lactose-containing dairy products from the diet (except for mature cheeses and caseinates); non-dairy sources of galactose, such as fruit and vegetables are allowed.

Patients were asked to keep a 3-day diary of their diet in the beginning and in the end of the study to be able to calculate the average arginine intake.

Assessments

All patients were evaluated at baseline and after intervention. Primary outcome was whole body galactose oxidative capacity. Secondary outcomes included erythrocyte GALT activity, as well as urinary galactose and galactitol levels. Additionally, pre-prandial amino acid profile was also performed.

Baseline assessments were done immediately before the initiation of Asparten® supplementation, and after treatment assessments were done immediately after suspension of Asparten® supplementation.

Primary outcome

Whole body galactose in vivo oxidative capacity was determined as previously described [17, 23]. Patients were administered 7 mg/kg [1-13C]-galactose tracer (0.039 mmol/kg, Cambridge Isotope Laboratories, Andover, USA) via a single bolus injection. Expired breath samples were collected into 10 mL Exetainer tubes (Labco limited, Lampeter, UK), which were filled directly from a mixing chamber in duplicate. A baseline breath sample was collected prior to [1-13C]-galactose injection (t = 0 min). During the first hour following injection, breath samples were collected at t = 5, 15, 30, 45 and 60 min. Thereafter, breath samples were collected at 30-min intervals until t = 360 min. Whole-body oxygen uptake (VO2) and carbon dioxide (VCO2) production were measured during three 60 min periods (t = 30–90, 150–210, and 270–330 min) using a ventilated hood system (Omnical, Maastricht University, Maastricht, the Netherlands). During the entire study period, subjects rested supine and were allowed to drink only water.

Expired breath samples were analyzed for 13C/12C ratio by gas chromatograph continuous flow isotope ratio mass spectrometry (Finnigan, Bremen, Germany). The isotopic enrichment was expressed as δ per mil difference between the 13C/12C ratio of the sample and a known laboratory reference standard [24].

The δ13C was then related to an international standard (PDB-1). The 13CO2 production from the oxidation of the infused [1-13C]-galactose tracer was subsequently calculated as:

$$ {\Pr}^{13}{\mathrm{CO}}_2=\frac{\left({\mathrm{TTR}}_{{\mathrm{CO}}_2}\ \mathrm{x}\ {\mathrm{VCO}}_2\right)}{(k)} $$

Where \( {\mathrm{TTR}}_{{\mathrm{CO}}_2} \) is the breath 13C/12C ratio at a given time point, VCO2 is the carbon dioxide production (L∙min− 1), k is the volume of CO2 (22.4 L∙mol− 1). Total 13CO2 production represents a minimal estimate of the total amount of [1-13C]-galactose that was oxidized within the experimental period. In addition, the cumulative percent of the [1-13C]-galactose tracer eliminated as 13CO2 in expired air (CUMPCD) was calculated.

Secondary outcomes

GALT enzymatic activity in RBC was performed as previously described [25]. Galactose and galactitol levels were measured in urine by GC/MS.

Amino acid profile was measured as described by Waterval et al. [26].

Diet

Dietary intake of arginine was determined by a 3-day food diary pre and post intervention and calculated as mean percentage of the total protein intake. The amount of arginine was considered to be 5% of the total protein intake [27].

Fibroblasts

Cultured fibroblasts from two wildtype and three classic galactosemic patients (Coriell GM1703, GM727 with p.Q188R/p.Q188R mutations and a Boston Children’s Hospital patient with p.Q188R/p.Q188P mutations) were grown in MEM media supplemented with 10% FBS at a 37 °C incubator with humidified atmosphere of 5% CO2. Arginine treatment was started by supplementing the growth media with 0, 0.1 mM or 1.0 mM of arginine (considered as day 0 of arginine treatment). On day 3 of the arginine treatment, cells were washed with ice cold PBS and pellets were harvested in cold PBS by scraping. The pellets were stored in − 80 °C until enzyme measurements. The GALT activity in cell lysates was measured using LC-MS/MS by a modified version of a method previously described for washed RBC [28]. Cell lysates were prepared by resuspending the pellets in 100–200 μL 0.5 M glycine buffer (pH 8.7) and sonicating for 15 s at level 1 (Sonic Dismembrator model 100, Fisher Scientific, USA) three times with one-minute intervals. The homogenate was then centrifuged at 15,800 g for 10 min at 4 °C (5402R, Eppendorf). Protein concentration was quantified using DC kit (Bio-RAD). AB Sciex QTrap 5500 mass spectrometer was used for quantification of the enzyme product. Arginine was measured in the cell culture supernatant by stable isotope dilution liquid chromatography tandem mass spectrometry (LC-MS/MS) using a 15N-L-Arginine internal standard (Cambridge Isotope Laboratories Inc., Tewksbury, MA, USA) with an Acquity™ Ultraperformance® liquid chromatography system coupled to a Quattro Premier tandem-quadrupole mass spectrometer (Waters Corporation, Milford, MA, USA).

Recombinant protein analysis

Expression and purification of human GALT was performed as previously described [6]. Differential scanning fluorimetry (DSF) was performed in a 96-well plate using an Mx3005p RT-PCR machine (Stratagene) with excitation and emission filters of 492 and 610 nm, respectively. Each 20 μL reaction consisted of 2 μL as-purified recombinant protein (final concentration of 2 μM, wildtype or p.Q188R) and 2 μL arginine at various concentrations (100 μM to 10 mM) in DSF buffer (150 mM NaCl, 10 mM HEPES pH 7.5) to which 2 μL SYPROrange, diluted 500-fold in DSF buffer from the manufacturer’s stock (Invitrogen) was added. Galactose (10 mM) was used as an indicator of ligand binding (positive control). Fluorescence intensities were measured at each 1 °C temperature increase from 25 to 96 °C with a ramp rate of 3 °C/min. A thermal shift of 3 °C or more is considered to be significant, though interpretation varies, and some papers report a value > 1.5 °C as significant.

Statistical analysis

Arginine aspartate’s effect in the primary and secondary outcomes was evaluated in IBM SPSS Statistics 23, using a paired t-test (double-sided) with a natural correction for non-normal populations. A p value less than 0.05 was considered statistically significant.

Notes

Abbreviations

CG: 

Classic galactosemia

CUMPCD: 

Cumulative percent of the dose

DSF: 

Differential scanning fluorimetry

GALT: 

Galactose-1-phosphate uridylyltransferase

METC: 

Medical Ethical Committee, In Dutch: Medisch Ethische Toetsingscommissie

NO : 

Nitric oxide

PDHc: 

Pyruvate dehydrogenase deficiency

RBC: 

Red blood cells

VCO2: 

Carbon dioxide production

VO2: 

Whole body oxygen uptake

Declarations

Acknowledgements

The authors wish to thank Britt van Erven, Martijn Lindhout and Joan Senden for practical assistance. The authors would like to thank Aristo Pharma Iberia SL for kindly providing Asparten®.

Funding

AIC was supported from the European Union’s Horizon 2020 research and innovation programme Marie Skłodowska-Curie Actions Individual Fellowship (MSCA-IF; grant agreement number 658967).

This study was financially supported by Stowisselkracht http://www.stofwisselkracht.nl/

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Authors’ contributions

Conception and design: MH, LJCL, WWY, GTB, JB, MERG, AIC. Collection and data analysis: MH, BD, LP, JT, JN, LJCL, SM, WWY, RWAP, LZ, DD, XH, WQ, GTB, JB, MERG, AIC. Supervision throughout the study: LJCL, WWY, GTB, JB, MERG, AIC. Manuscript writing: MH, BD, MERG, AIC. Manuscript editing and final approval: MH, BD, LP, JT, JN, LJCL, SM, WWY, DD, GTB, JB, MERG, AIC.

Ethics approval and consent to participate

The Medical Ethical Committee (Medisch Ethische Toetsingscommissie, METC) of the Maastricht University Medical Center + approved the clinical study (METC reference: 172012). Written consent was obtained from all four participants before the beginning of the study.

This study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines, the Principles of the Declaration of Helsinki. Fibroblast samples GM1703 AND GM727 were acquired from Coriell Institute. The other fibroblast line was generated through a Boston Children’s Hospital IRB approved protocol.

Consent for publication

Consent was obtained from all patients for publication.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Clinical Genetics, Maastricht University Medical Center +, Maastricht, The Netherlands
(2)
Department of Pediatrics, Maastricht University Medical Center +, Maastricht, The Netherlands
(3)
GROW-School for Oncology and Developmental Biology, University of Maastricht, Maastricht, The Netherlands
(4)
Department of Dietetics, Maastricht University Medical Center +, Maastricht, The Netherlands
(5)
Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center +, Maastricht, The Netherlands
(6)
Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
(7)
Department of Laboratory Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
(8)
The Manton Center for Orphan Disease Research, Division of Genetics and Genomics, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA

References

  1. Bosch AM, Grootenhuis MA, Bakker HD, Heijmans HS, Wijburg FA, Last BF. Living with classical galactosemia: health-related quality of life consequences. Pediatrics. 2004;113(5):e423–8.View ArticleGoogle Scholar
  2. Waisbren SE, Potter NL, Gordon CM, Green RC, Greenstein P, Gubbels CS, et al. The adult galactosemic phenotype. J Inherit Metab Dis. 2012;35(2):279–86.View ArticleGoogle Scholar
  3. Coelho AI, Rubio-Gozalbo ME, Vicente JB, Rivera I. Sweet and sour: an update on classic galactosemia. J Inherit Metab Dis. 2017;40(3):325–42.View ArticleGoogle Scholar
  4. McCorvie TJ, Gleason TJ, Fridovich-Keil JL, Timson DJ. Misfolding of galactose 1-phosphate uridylyltransferase can result in type I galactosemia. Biochim Biophys Acta. 2013;1832(8):1279–93.View ArticleGoogle Scholar
  5. Coelho AI, Trabuco M, Ramos R, Silva MJ, Tavares de Almeida I, Leandro P, et al. Functional and structural impact of the most prevalent missense mutations in classic galactosemia. Mol Genet Genomic Med. 2014;2(6):484–96.View ArticleGoogle Scholar
  6. McCorvie TJ, Kopec J, Pey AL, Fitzpatrick F, Patel D, Chalk R, et al. Molecular basis of classic galactosemia from the structure of human galactose 1-phosphate uridylyltransferase. Hum Mol Genet. 2016;25(11):2234–44.View ArticleGoogle Scholar
  7. Coss KP, Doran PP, Owoeye C, Codd MB, Hamid N, Mayne PD, et al. Classical Galactosaemia in Ireland: incidence, complications and outcomes of treatment. J Inherit Metab Dis. 2013;36(1):21–7.View ArticleGoogle Scholar
  8. Kim YE, Hipp MS, Bracher A, Hayer-Hartl M, Hartl FU. Molecular chaperone functions in protein folding and proteostasis. Annu Rev Biochem. 2013;82:323–55.View ArticleGoogle Scholar
  9. Muntau AC, Leandro J, Staudigl M, Mayer F, Gersting SW. Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators. J Inherit Metab Dis. 2014;37(4):505–23.View ArticleGoogle Scholar
  10. Matalonga L, Gort L, Ribes A. Small molecules as therapeutic agents for inborn errors of metabolism. J Inherit Metab Dis. 2017;40(2):177–93.View ArticleGoogle Scholar
  11. Arakawa T, Tsumoto K. The effects of arginine on refolding of aggregated proteins: not facilitate refolding, but suppress aggregation. Biochem Biophys Res Commun. 2003;304(1):148–52.View ArticleGoogle Scholar
  12. Baynes BM, Wang DI, Trout BL. Role of arginine in the stabilization of proteins against aggregation. Biochemistry. 2005;44(12):4919–25.View ArticleGoogle Scholar
  13. Coelho AI, Trabuco M, Silva MJ, de Almeida IT, Leandro P, Rivera I, et al. Arginine functionally improves clinically relevant human Galactose-1-phosphate Uridylyltransferase (GALT) variants expressed in a prokaryotic model. JIMD Rep. 2015;23:1–6.View ArticleGoogle Scholar
  14. Berendse K, Ebberink MS, Ijlst L, Poll-The BT, Wanders RJ, Waterham HR. Arginine improves peroxisome functioning in cells from patients with a mild peroxisome biogenesis disorder. Orphanet J Rare Dis. 2013;8:138.View ArticleGoogle Scholar
  15. Sorlin A, Briand G, Cheillan D, Wiedemann A, Montaut-Verient B, Schmitt E, et al. Effect of l-arginine in one patient with peroxisome biogenesis disorder due to PEX12 deficiency. Neuropediatrics. 2016;47(3):179–81.View ArticleGoogle Scholar
  16. Joao Silva M, Pinheiro A, Eusebio F, Gaspar A, Tavares de Almeida I, Rivera I. Pyruvate dehydrogenase deficiency: identification of a novel mutation in the PDHA1 gene which responds to amino acid supplementation. Eur J Pediatr. 2009;168(1):17–22.View ArticleGoogle Scholar
  17. Berry GT, Singh RH, Mazur AT, Guerrero N, Kennedy MJ, Chen J, et al. Galactose breath testing distinguishes variant and severe galactose-1-phosphate uridyltransferase genotypes. Pediatr Res. 2000;48(3):323–8.View ArticleGoogle Scholar
  18. Dioguardi FS. To give or not to give? Lessons from the arginine paradox. J Nutrigenet Nutrigenomics. 2011;4(2):90–8.View ArticleGoogle Scholar
  19. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J. 2001;357(Pt 3):593–615.View ArticleGoogle Scholar
  20. Wang MY, Desforges JF. Red cell survival in galactosemia. J Pediatr. 1996;69(4):619–23.View ArticleGoogle Scholar
  21. Franco RS. Measurement of red cell lifespan and aging. Transfus Med Hemother. 2012;39(5):302–7.View ArticleGoogle Scholar
  22. Gámez A, Yuste-Checa P, Brasil S, Briso-Montiano Á, Desviat LR, Ugarte M, et al. Protein misfolding diseases: prospects of pharmacological treatment. Clin Genet. 2018;93(3):450–8.View ArticleGoogle Scholar
  23. Berry GT, Moate PJ, Reynolds RA, Yager CT, Ning C, Boston RC, et al. The rate of de novo galactose synthesis in patients with galactose-1-phosphate uridyltransferase deficiency. Mol Genet Metab. 2004;81(1):22–30.View ArticleGoogle Scholar
  24. Craig H. Isotopic standards for carbon and oxygen and correction factors for mass-spectrometric analysis of carbon dioxide. Geochim Cosmoch Acta. 1957;12(1–2):133–49.View ArticleGoogle Scholar
  25. Lindhout M, Rubio-Gozalbo ME, Bakker JA, Bierau J. Direct non-radioactive assay of galactose-1-phosphate:uridyltransferase activity using high performance liquid chromatography. Clin Chim Acta. 2010;411(13–14):980–3.View ArticleGoogle Scholar
  26. Waterval WA, Scheijen JL, Ortmans-Ploemen MM, Habets-van der Poel CD, Bierau J. Quantitative UPLC-MS/MS analysis of underivatised amino acids in body fluids is a reliable tool for the diagnosis and follow-up of patients with inborn errors of metabolism. Clin Chim Acta. 2009;407(1–2):36–42.View ArticleGoogle Scholar
  27. Souci SW, Fachmann W, Kraut H. Food composition and nutrition tables. 4th ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; 1989.Google Scholar
  28. Li Y, Ptolemy AS, Harmonay L, Kellogg M, Berry GT. Ultra fast and sensitive liquid chromatography tandem mass spectrometry based assay for galactose-1-phosphate uridylyltransferase and galactokinase deficiencies. Mol Genet Metab. 2011;102(1):33–40.View ArticleGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement